 |
Articles: Drug Trials |
Prior Articles
Multiple-blind: Towards a new blinding protocol for future generations of clinical trials
Medical Hypotheses, 06/04/09
Making trials matter: pragmatic and explanatory trials and the problem of applicability
Trials, 06/04/09
Free full text
Evaluation and Recommendations on Good Clinical Laboratory Practice Guidelines for Phase I-III Clinical Trials
PLoS Medicine, 06/04/09
Free full text
Paclitaxel Poliglumex (OPAXIO) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
Cell Therapeutics, 06/04/09
Free full text
One-year Phase III study confirms Ilaris offers long-term remission in patients with CAPS, a severe lifelong auto-inflammatory disease
Novartis, 06/04/09
Free full text
New Findings Demonstrate Potential Benefits of GATTEX(TM) (teduglutide) in Phase 3 Study of Patients with Short Bowel Syndrome
NPS Pharmaceuticals, 06/04/09
Free full text
Assumes Primary Responsibility for Alemtuzumab in Multiple Sclerosis; Expands Hematologic Oncology Portfolio
Genzyme, 06/03/09
Free full text
Cytokinetics Presents Clinical Data Relating To Ispinesib in Patients with Metastatic Breast Cancer at the 2009 Annual Meeting of the American Society of Clinical Oncology
Cytokinetics, 06/03/09
Free full text
Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Cell Therapeutics, 06/03/09
Free full text
Active Biotech Completes Patient Enrollment to ANYARA Phase III Clinical Trial
Active Biotech, 06/02/09
Free full text
GSKs Pazopanib significantly delayed tumor progression in patients with advanced kidney cancer
GlaxoSmithKline, 06/02/09
Free full text
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
Onyx Pharmaceuticals, 06/02/09
Free full text
Positive Results from Salix Pivotal Phase III Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE) Presented at Digestive Disease Week
Salix Pharmaceuticals, 06/02/09
Free full text
Phase III study data with vandetanib (ZACTIMA) in patients with advanced non-small cell lung cancer (NSCLC) presented at American Society of Clinical Oncology
AstraZeneca, 06/01/09
Free full text
Maintenance treatment with Avastin and Tarceva in combination helps lung cancer patients live longer without their disease worsening
Roche, 06/01/09
Free full text
Calcimimetics: A Review of the Recent Literature
Kidney, 06/01/09 VITA-D: Cholecalciferol substitution in vitamin D deficient kidney transplant recipients: A randomized, placebo-controlled study to evaluate the post-transplant outcome
Trials, 06/01/09
Free full text
Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab
Bristol Myers-Squibb Company, 06/01/09
Free full text
Exelixis and BMS Report Phase 2 Data to Be Presented at ASCO for XL184 in Patients with Previously Treated Glioblastoma Multiforme
Bristol Myers-Squibb Company, 06/01/09
Free full text
Subset Data from Two Randomized Phase 3 Trials Show TYSABRI(R) Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNFa Therapy
Elan, 06/01/09
Free full text
|
|
Receive free subspecialty "5-minute updates" via email
|
|
Indexed Journals: U.S.Pharmacist, FDA Drug Alerts, Pharmiweb
more...
|
250 Available Pages
|
|
